Date: 2 July 2020
Time: 12h30 –14h00
Livestream via Zoom
The treatment of drug-resistant tuberculosis (DR-TB) is often influenced by adverse drug reactions and can impact patient outcomes. Thus, the WHO recommends targeted spontaneous reporting for special populations, such as those living with DR-TB, who are specifically monitored for adverse events. While the incidence of adverse events associated with DR-TB medication are well documented, the reporting to regulatory bodies is lacking. The primary aim of the study was to understand the current adverse event reporting practices in specialised DR-TB treatment facilities in South Africa.
Prof Priscilla Reddy, Health and Wellbeing, Human and Social Capabilities, HSRC
Dr Razia Gaida & Mr Adlai Davids, Human and Social Capabilities , HSRC
Kindly RSVP by 1 July 2020
For further information contact: Arlene Grossberg | E: firstname.lastname@example.org
The HSRC seminar series is funded by the Department of Science and Innovation (DSI). The views and opinions expressed therein as well as findings and statements of the seminar series do not necessarily represent the views of the DSI. Please also note that this seminar may be recorded and published on the HSRC podcast channel.
Please contact Arlene Grossberg (email@example.com) to unsubscribe.
Zoom link: https://zoom.us/j/91967457048